Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(DLBCL)

NCT01499303 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01499303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01499303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(DLBCL)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2011
Completion date
October 31, 2013
Enrollment
101 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma